iShares Biotechnology ETF $IBB Shares Purchased by NTV Asset Management LLC

NTV Asset Management LLC boosted its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 4.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,028 shares of the financial services provider’s stock after acquiring an additional 3,043 shares during the quarter. iShares Biotechnology ETF accounts for approximately 1.3% of NTV Asset Management LLC’s investment portfolio, making the stock its 13th biggest position. NTV Asset Management LLC owned 0.13% of iShares Biotechnology ETF worth $14,111,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of America Corp DE lifted its position in shares of iShares Biotechnology ETF by 10.8% during the first quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock worth $1,225,767,000 after purchasing an additional 707,343 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of iShares Biotechnology ETF by 1.0% in the first quarter. Royal Bank of Canada now owns 737,128 shares of the financial services provider’s stock valued at $124,464,000 after purchasing an additional 7,434 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of iShares Biotechnology ETF by 5.4% in the first quarter. Janney Montgomery Scott LLC now owns 652,818 shares of the financial services provider’s stock valued at $110,228,000 after purchasing an additional 33,268 shares during the period. Cetera Investment Advisers boosted its stake in shares of iShares Biotechnology ETF by 9.4% in the first quarter. Cetera Investment Advisers now owns 128,530 shares of the financial services provider’s stock valued at $21,702,000 after purchasing an additional 10,994 shares during the period. Finally, Albion Financial Group UT grew its holdings in shares of iShares Biotechnology ETF by 1.0% in the third quarter. Albion Financial Group UT now owns 120,782 shares of the financial services provider’s stock valued at $25,428,000 after purchasing an additional 1,147 shares in the last quarter. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Performance

Shares of IBB stock opened at $207.74 on Friday. iShares Biotechnology ETF has a fifty-two week low of $154.62 and a fifty-two week high of $217.12. The company has a 50 day moving average price of $207.88 and a 200 day moving average price of $189.30.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 18th. Shareholders of record on Tuesday, September 15th were given a $0.0112 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $0.04 annualized dividend and a yield of 0.0%. This is a drop from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.